Ved en AT- analyse (as- treated), hvor manglende værdier blev ekskluderet, var andelen af patienter med HIV RNA < 400 kopier/ ml (< 50 kopier/ ml) i REYATAZ + ritonavir- armen og lopinavir + ritonavir- armen henholdsvis 55% (40%) og 56% (46%).
By as-treated analysis, excluding missing values, the proportions of patients with HIV RNA < 400 copies/ ml (< 50 copies/ ml) in the REYATAZ + ritonavir arm and the lopinavir + ritonavir arm were 55% (40%) and 56% (46%), respectively.